Literature DB >> 9584219

Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor.

R A Leppik1, S Lazareno, A Mynett, N J Birdsall.   

Abstract

The purpose of this study was to determine whether there is a well-defined allosteric site on the human alpha2A-adrenergic receptor. To explore this question, we examined the effects of amiloride analogues on the dissociation of [3H]yohimbine, [3H]rauwolscine, and [3H]RX821002. The dissociation data fitted well to an equation derived from the ternary complex allosteric model with amiloride analogue concentration and time as two independent variables. The estimated maximal increase in the [3H]yohimbine dissociation rate caused by the 5-N-alkyl amilorides varied from 2-fold for the parent amiloride to 140- and 160-fold for 5-(N, N-hexamethylene)-amiloride and 5-(N-ethyl-N-isopropyl)-amiloride, respectively. The calculated log affinities at the yohimbine-occupied receptor ranged from 1.75 for 5-(N-ethyl-N-isopropyl)-amiloride to 2.5 for 5-(N, N-hexamethylene)-amiloride. The increase in affinity found at the yohimbine-occupied receptor was not correlated with increase in size of the 5-N-alkyl side chain, in contrast to the situation found at the unoccupied receptor. The effect of competition between two amilorides on yohimbine dissociation also was explored. The data obtained were well fitted by the equation derived from the relevant model, with the off-rate increases caused by 5-(N, N-hexamethylene)-amiloride being either decreased or increased by the competing amiloride analogue in line with predictions, and the parameters derived from the fits were in good agreement with those obtained in the above dissociation assays. Thus, the data are compatible with the amilorides competing at the one allosteric site on the alpha2A-adrenergic receptor and rules out the possibility that the amilorides are acting in a nonspecific fashion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584219

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 2.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

3.  Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues.

Authors:  S R Hoare; M C Coldwell; D Armstrong; P G Strange
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding.

Authors:  Zhan-Guo Gao; Liaman Mamedova; Susanna Tchilibon; Ariel S Gross; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-07-15       Impact factor: 5.858

5.  Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors.

Authors:  Markus Kathmann; Karsten Flau; Agnes Redmer; Christian Tränkle; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-18       Impact factor: 3.000

Review 6.  Allosteric modulation of the adenosine family of receptors.

Authors:  Zhan-Guo Gao; Soo-Kyung Kim; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  Mini Rev Med Chem       Date:  2005-06       Impact factor: 3.862

Review 7.  Allosteric modulation of G protein-coupled receptors by amiloride and its derivatives. Perspectives for drug discovery?

Authors:  Arnault Massink; Tasia Amelia; Alex Karamychev; Adriaan P IJzerman
Journal:  Med Res Rev       Date:  2019-09-08       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.